Characterization of a novel Flpo recombinase line targeting nigral dopamine neurons

靶向黑质多巴胺神经元的新型 Flpo 重组酶系的表征

基本信息

  • 批准号:
    9434206
  • 负责人:
  • 金额:
    $ 8.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-01 至 2019-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary Characterization of a novel Flpo recombinase line targeting nigral dopamine neurons The dopamine (DA) neurons of the substantia nigra pars compacta (SNc) have been extensively studied because of their selective vulnerability to degeneration during Parkinson's disease (PD) progression. The DA neurons of the closely neighboring ventral tegmental area (VTA) are largely spared during PD progression; a phenomenon that remains poorly understood. Studies attempting to separate SNc and VTA function using modern genetic tools have been limited by the lack of recombinase lines that effectively separate these two nuclei. Recent studies have shown that aldehyde dehydrogenase 1a1 (Aldh1a1) is expressed selectively in SNc DA neurons and this subpopulation of DA neurons undergoes the most extensive degeneration in sporadic PD. Also it has been recently shown that Aldh1a1 is capable of participating in GABA synthesis in a pathway independent of the classic GABA biosynthetic pathway. Thus Aldh1a1+ DA neurons represent an anatomically and neurochemically distinct population of DA neurons relevant to PD. To gain genetic access to this population we have developed a Flpo recombinase knock-in line at the mouse Aldh1a1 locus. Using this novel Aldh1a12A-Flpo line in an intersectional approach with the dopamine transporter Cre line (Slc6a3IRES-Cre) we will be able to gain genetic access to both Aldh1a1+ and Aldh1a1- DA neurons. This proposal is designed to test the feasibility of using Aldh1a12A-Flpo to selectively target SNc DA neurons and to determine their target fields and diversity of molecular phenotypes. We also evaluate the utility of intersectional approaches to specify VTA DA neurons using Aldh1a12A-Flpo with Slc6a3IRES-Cre transgenic mice.
项目摘要 新型FLPO重组酶系的靶向ni核多巴胺神经元的表征 已广泛研究了黑质nigra pars commacta(SNC)的多巴胺(DA)神经元 由于它们在帕金森氏病(PD)进展过程中对退化的选择性脆弱性。 DA 在PD进展过程中,紧密相邻的腹侧对接区域(VTA)的神经元在很大程度上被保留;一个 现象仍然很熟悉。试图使用SNC和VTA功能的研究 现代遗传工具受到重组酶线的缺乏限制 核。最近的研究表明,醛中选择性地表达了醛脱氢酶1a1(Aldh1a1) SNC DA神经元和DA神经元的这种亚群经历了最广泛的变性 零星PD。最近,最近已经证明了Aldh1a1能够参与A中的GABA合成 途径独立于经典的GABA生物合成途径。因此,aldh1a1+ da神经元代表 与PD相关的DA神经元的解剖学和神经化学上不同的人群。获取遗传获取 我们在小鼠ALDH1A1基因座上开发了FLPO重组酶敲门线。使用此 新颖的ALDH1A12A-FLPO系在与多巴胺转运蛋白CRE系(SLC6A3IRES-CRE)的交叉方法中 将能够获得对AldH1A1+和AldH1A1-DA神经元的遗传获取。该建议旨在 测试使用Aldh1a12a-FLPO选择性靶向SNC DA神经元并确定其靶标的可行性 分子表型的场和多样性。我们还评估了交叉方法的实用性 使用SLC6A3IRES-CRE转基因小鼠使用ALDH1A12A-FLPO指定VTA DA神经元。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

VALINA L. DAWSON的其他基金

Innate immune memory promotes neural damage in the ART suppressed HIV infected brain
先天免疫记忆促进 ART 抑制的 HIV 感染大脑中的神经损伤
  • 批准号:
    10701935
    10701935
  • 财政年份:
    2022
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Imaging Mass Spectrometry-Based Metabolomic Analysis of the Alzheimer's Brain
基于成像质谱的阿尔茨海默病大脑代谢组学分析
  • 批准号:
    10516253
    10516253
  • 财政年份:
    2022
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Innate immune memory promotes neural damage in the ART suppressed HIV infected brain
先天免疫记忆促进 ART 抑制的 HIV 感染大脑中的神经损伤
  • 批准号:
    10536461
    10536461
  • 财政年份:
    2022
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Imaging Mass Spectrometry-Based Metabolomic Analysis of the Alzheimer's Brain
基于成像质谱的阿尔茨海默病大脑代谢组学分析
  • 批准号:
    10705238
    10705238
  • 财政年份:
    2022
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Targeting cell signaling pathways to disrupt drug abuse
靶向细胞信号通路以破坏药物滥用
  • 批准号:
    10404512
    10404512
  • 财政年份:
    2018
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Targeting cell signaling pathways to disrupt drug abuse
靶向细胞信号通路以破坏药物滥用
  • 批准号:
    10171821
    10171821
  • 财政年份:
    2018
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Thorase Regulation of the Actions of Cocaine
Thorase 对可卡因作用的调节
  • 批准号:
    10404517
    10404517
  • 财政年份:
    2018
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Thorase Regulation of the Actions of Cocaine
Thorase 对可卡因作用的调节
  • 批准号:
    10171826
    10171826
  • 财政年份:
    2018
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Action of SARS CoV2 in Human Brain Cultures
SARS CoV2 在人脑培养物中的作用
  • 批准号:
    10173327
    10173327
  • 财政年份:
    2018
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
LRRK2 Biology in Parkinson's Disease
LRRK2 在帕金森病中的生物学作用
  • 批准号:
    8882848
    8882848
  • 财政年份:
    2014
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:

相似海外基金

Focused ultrasound for memory disorders
聚焦超声治疗记忆障碍
  • 批准号:
    10638189
    10638189
  • 财政年份:
    2023
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Designing novel therapeutics for Alzheimer’s disease using structural studies of tau
利用 tau 蛋白结构研究设计治疗阿尔茨海默病的新疗法
  • 批准号:
    10678341
    10678341
  • 财政年份:
    2023
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Imaging transcriptomics across developmental stages of early psychotic illness
早期精神病发展阶段的转录组学成像
  • 批准号:
    10664783
    10664783
  • 财政年份:
    2023
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
Altered microglia states and microglia-endothelial cell axis in relation to white matter disease progression in VCID
VCID 中小胶质细胞状态和小胶质细胞内皮细胞轴的改变与白质疾病进展相关
  • 批准号:
    10738860
    10738860
  • 财政年份:
    2023
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别:
The role of PPARγ in astrocyte pathobiology after exposure to repetitive mild traumatic brain injury
PPARγ 在重复性轻度脑外伤后星形胶质细胞病理学中的作用
  • 批准号:
    10739968
    10739968
  • 财政年份:
    2023
  • 资助金额:
    $ 8.18万
    $ 8.18万
  • 项目类别: